Table 5. Clinical events in follow-up.

Events	High-dose statin n (%)	Control n (%)	P
Stable
Death	12(1.6)	13(2.7)	0.67
Spontaneous MI	7(1.0)	7(1.3)	0.50
TVR	31(4.2)	32(6.6)	0.23
MACE	50(6.8)	52(10.7)	0.12
ACS
Death	3(0.4)	9(1.3)	0.12
Spontaneous MI	15(2.2)	20(3.0)	0.40
TVR	16(2.4)	34(5.0)	0.01
MACE	34(5.0)	63(9.3)	0.003
Mixed presentation
Death	1(0.1)	1(0.1)	0.50
Spontaneous MI	1(0.1)	0(0)	0.51
TVR	0(0)	0(0)	NA
MACE	2(0.2)	1(0.1)	0.67
Statin-naive
Death	13(1.1)	20(1.6)	0.28
Spontaneous MI	21(1.7)	24(2.0)	0.80
TVR	41(3.4)	59(4.9)	0.09
MACE	75(6.2)	103(8.5)	0.02
Prior low-dose statin
Death	3(0.5)	3(0.8)	0.25
Spontaneous MI	2(0.3)	3(0.8)	0.07
TVR	6(0.9)	7(1.7)	0.04
MACE	11(1.7)	13(3.3)	0.003
Overall
Death	16(0.7)	23(1.2)	0.15
Spontaneous MI	23(1.1)	27(1.4)	0.37
TVR	47(2.2)	66(3.5)	0.02
MACE	86(4.0)	116(6.1)	0.002

Spontaneous MI = spontaneous myocardial infarction; ACS = acute coronary syndrome;

TVR = target vessel revascularization; MACE = major adverse cardiovascular events;

NA = not available.